KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Other Operating Expenses (2016 - 2026)

Biocryst Pharmaceuticals filings provide 14 years of Other Operating Expenses readings, the most recent being $9.5 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 56.25% to $9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.1 million, a 55.47% increase, with the full-year FY2025 number at $19.1 million, up 55.47% from a year prior.
  • Other Operating Expenses hit $9.5 million in Q4 2025 for Biocryst Pharmaceuticals, up from $2.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $9.5 million in Q4 2025 to a low of $238000.0 in Q1 2022.
  • Median Other Operating Expenses over the past 5 years was $1.6 million (2023), compared with a mean of $2.5 million.
  • Biggest five-year swings in Other Operating Expenses: soared 8431.88% in 2021 and later crashed 95.96% in 2022.
  • Biocryst Pharmaceuticals' Other Operating Expenses stood at $419000.0 in 2021, then surged by 495.7% to $2.5 million in 2022, then crashed by 41.63% to $1.5 million in 2023, then soared by 318.26% to $6.1 million in 2024, then surged by 56.25% to $9.5 million in 2025.
  • The last three reported values for Other Operating Expenses were $9.5 million (Q4 2025), $2.2 million (Q3 2025), and $2.8 million (Q2 2025) per Business Quant data.